Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris [3]

British Journal of Dermatology

Volumn 153, Issue 4, 2005, Pages 843-844

  De Groot, M ^a   De Rie, M A ^a   Bos, J D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; EFALIZUMAB;

ADULT; BATH; CASE REPORT; CLINICAL FEATURE; DERMATITIS; HISTOPATHOLOGY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SKIN BIOPSY; ULTRAVIOLET B RADIATION;

EID: 26244467740     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06840.x     Document Type: Letter

References (7)

1. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-80.
2. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
3. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke DA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-Cdha antibody. Arch Dermatol 2002; 138:591-600.
4. Cather JC, Cather JC, Menter A. Modulating T-cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 3:361-370.
5. Gottlieb AB, Miller B, Lowe N et al. Subcutaneously administered efalizumab (anti-CDHa) improves signs and symptoms of moderate to severe plague psoriasis. J Cutan Med Surg 2003; 7(3):198-207.
6. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49:S98-104.
7. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 2004; 3:77-9.